SK282277B6 - Tableta alebo kapsula na prehĺtanie a spôsob jej výroby - Google Patents
Tableta alebo kapsula na prehĺtanie a spôsob jej výroby Download PDFInfo
- Publication number
- SK282277B6 SK282277B6 SK1197-99A SK119799A SK282277B6 SK 282277 B6 SK282277 B6 SK 282277B6 SK 119799 A SK119799 A SK 119799A SK 282277 B6 SK282277 B6 SK 282277B6
- Authority
- SK
- Slovakia
- Prior art keywords
- paracetamol
- tablet
- sodium bicarbonate
- tablets
- capsule
- Prior art date
Links
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 6
- 238000000034 method Methods 0.000 title claims description 6
- 239000007916 tablet composition Substances 0.000 title description 2
- 239000007963 capsule composition Substances 0.000 title 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims abstract description 102
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims abstract description 98
- 229960005489 paracetamol Drugs 0.000 claims abstract description 96
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims abstract description 49
- 235000017557 sodium bicarbonate Nutrition 0.000 claims abstract description 49
- 239000002775 capsule Substances 0.000 claims abstract description 25
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 10
- 238000002156 mixing Methods 0.000 claims abstract description 5
- 230000009747 swallowing Effects 0.000 claims description 4
- 239000013543 active substance Substances 0.000 claims description 3
- 239000002671 adjuvant Substances 0.000 claims description 3
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 abstract description 15
- 239000003826 tablet Substances 0.000 description 95
- 229920002472 Starch Polymers 0.000 description 22
- 235000019698 starch Nutrition 0.000 description 22
- 239000008107 starch Substances 0.000 description 21
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical class [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 17
- 239000000654 additive Substances 0.000 description 16
- 238000010521 absorption reaction Methods 0.000 description 14
- 239000000203 mixture Substances 0.000 description 14
- 230000000996 additive effect Effects 0.000 description 12
- 239000004615 ingredient Substances 0.000 description 12
- 235000021355 Stearic acid Nutrition 0.000 description 11
- 240000008042 Zea mays Species 0.000 description 11
- 235000016383 Zea mays subsp huehuetenangensis Nutrition 0.000 description 11
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 11
- 235000009973 maize Nutrition 0.000 description 11
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 11
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 11
- 239000008117 stearic acid Substances 0.000 description 11
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 10
- 229920003080 Povidone K 25 Polymers 0.000 description 10
- 229940069338 potassium sorbate Drugs 0.000 description 10
- 235000010241 potassium sorbate Nutrition 0.000 description 10
- 239000004302 potassium sorbate Substances 0.000 description 10
- 229940100487 povidone k25 Drugs 0.000 description 10
- 239000000454 talc Substances 0.000 description 10
- 229910052623 talc Inorganic materials 0.000 description 10
- 210000002966 serum Anatomy 0.000 description 8
- 229910000019 calcium carbonate Inorganic materials 0.000 description 7
- 239000008187 granular material Substances 0.000 description 7
- 230000037406 food intake Effects 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 229940069428 antacid Drugs 0.000 description 5
- 239000003159 antacid agent Substances 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 230000000052 comparative effect Effects 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 208000019695 Migraine disease Diseases 0.000 description 3
- 239000000730 antalgic agent Substances 0.000 description 3
- 230000001458 anti-acid effect Effects 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 238000005469 granulation Methods 0.000 description 3
- 230000003179 granulation Effects 0.000 description 3
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 3
- 239000001095 magnesium carbonate Substances 0.000 description 3
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 206010067125 Liver injury Diseases 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 238000007907 direct compression Methods 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 231100000234 hepatic damage Toxicity 0.000 description 2
- 230000008818 liver damage Effects 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 206010027599 migraine Diseases 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 239000004266 EU approved firming agent Substances 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 206010027603 Migraine headaches Diseases 0.000 description 1
- 239000004368 Modified starch Substances 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 229940125716 antipyretic agent Drugs 0.000 description 1
- 239000003434 antitussive agent Substances 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 208000029618 autoimmune pulmonary alveolar proteinosis Diseases 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- 239000000850 decongestant Substances 0.000 description 1
- 229940124581 decongestants Drugs 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000007938 effervescent tablet Substances 0.000 description 1
- 239000002895 emetic Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 230000030136 gastric emptying Effects 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- TTWJBBZEZQICBI-UHFFFAOYSA-N metoclopramide Chemical compound CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC TTWJBBZEZQICBI-UHFFFAOYSA-N 0.000 description 1
- 229960004503 metoclopramide Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 239000000820 nonprescription drug Substances 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000000955 prescription drug Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000007944 soluble tablet Substances 0.000 description 1
- 229940071117 starch glycolate Drugs 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Detergent Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9704524.9A GB9704524D0 (en) | 1997-03-05 | 1997-03-05 | Composition |
| PCT/EP1998/001284 WO1998038983A2 (en) | 1997-03-05 | 1998-02-27 | Swallow tablet comprising paracetamol |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| SK119799A3 SK119799A3 (en) | 2000-02-14 |
| SK282277B6 true SK282277B6 (sk) | 2002-01-07 |
Family
ID=10808717
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SK1197-99A SK282277B6 (sk) | 1997-03-05 | 1998-02-27 | Tableta alebo kapsula na prehĺtanie a spôsob jej výroby |
Country Status (35)
| Country | Link |
|---|---|
| US (1) | US6316025B1 (cs) |
| EP (1) | EP0981334B1 (cs) |
| JP (1) | JP2001513801A (cs) |
| KR (1) | KR100465895B1 (cs) |
| CN (1) | CN100389751C (cs) |
| AP (1) | AP1084A (cs) |
| AR (1) | AR011919A1 (cs) |
| AT (1) | ATE240720T1 (cs) |
| AU (1) | AU721851B2 (cs) |
| BG (1) | BG64348B1 (cs) |
| BR (1) | BR9807992A (cs) |
| CA (1) | CA2283408C (cs) |
| CO (1) | CO4940406A1 (cs) |
| CY (1) | CY2367B1 (cs) |
| CZ (1) | CZ294078B6 (cs) |
| DE (1) | DE69814850T2 (cs) |
| DK (1) | DK0981334T3 (cs) |
| EA (1) | EA001918B1 (cs) |
| ES (1) | ES2199435T3 (cs) |
| GB (1) | GB9704524D0 (cs) |
| HU (1) | HU224983B1 (cs) |
| ID (1) | ID22233A (cs) |
| IL (1) | IL131552A (cs) |
| MY (1) | MY119722A (cs) |
| NO (1) | NO327456B1 (cs) |
| NZ (1) | NZ337418A (cs) |
| PE (1) | PE68899A1 (cs) |
| PL (1) | PL190988B1 (cs) |
| PT (1) | PT981334E (cs) |
| SK (1) | SK282277B6 (cs) |
| TR (1) | TR199902175T2 (cs) |
| TW (1) | TW508242B (cs) |
| UA (1) | UA59388C2 (cs) |
| WO (1) | WO1998038983A2 (cs) |
| ZA (1) | ZA981832B (cs) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6211246B1 (en) | 1999-06-10 | 2001-04-03 | Mcneil-Ppc, Inc. | Rapidly absorbed liquid compositions |
| NZ508291A (en) * | 1999-11-24 | 2002-09-27 | Mcneil Ppc Inc | Use of acetaminophen in a medicament for treating migraine symptoms |
| GB0006897D0 (en) * | 2000-03-23 | 2000-05-10 | Smithkline Beecham Plc | Medicaments |
| GB0114069D0 (en) * | 2001-06-08 | 2001-08-01 | Smithkline Beecham Plc | Composition |
| GB0129117D0 (en) * | 2001-12-05 | 2002-01-23 | Glaxo Group Ltd | Pharmaceutical composition |
| BRPI0409127A (pt) * | 2003-04-11 | 2006-03-28 | Pfizer | combinação farmacêutica compreendendo eletriptano e bicarbonato de sódio |
| JP2008500288A (ja) * | 2004-05-28 | 2008-01-10 | イメイジノット ピーティーワイ エルティーディー | 経口治療用化合物の供給系 |
| US8216610B2 (en) * | 2004-05-28 | 2012-07-10 | Imaginot Pty Ltd. | Oral paracetamol formulations |
| WO2005115344A1 (en) * | 2004-05-28 | 2005-12-08 | Imaginot Pty Ltd | Oral delivery system |
| DE102004042139B4 (de) * | 2004-08-31 | 2009-06-10 | Aristocon Verwaltungs- Gmbh | Perorale Darreichungsformen zur Erzielung eines Retardierungseffektes nach der Arzneimitteleinnahme mit einer Mahlzeit |
| DE602005020048D1 (de) * | 2004-10-28 | 2010-04-29 | Novartis Ag | Zusammensetzung mit acetaminophen, koffein und aspirin zusammen mit einem alkaliwirkstoff für verbesserte absorption |
| US9060950B2 (en) * | 2005-06-13 | 2015-06-23 | Paul H. Rosenberg, Proximate Concepts, LLC. | Emetic embedded capsule |
| JP2008543851A (ja) * | 2005-06-13 | 2008-12-04 | ポール・ローゼンバーグ | 催吐剤封入カプセル |
| KR100702069B1 (ko) * | 2005-10-31 | 2007-03-30 | (주)이엘티사이언스 | 파라세타몰 경구용 수용산제 복합조성물 및 그 제조방법 |
| AU2006317530B2 (en) | 2005-11-28 | 2011-09-01 | Imaginot Pty Ltd | Oral therapeutic compound delivery system |
| GB0607085D0 (en) * | 2006-04-07 | 2006-05-17 | Smithkline Beecham Corp | Novel compositions |
| US20080014228A1 (en) * | 2006-07-14 | 2008-01-17 | Olivia Darmuzey | Solid form |
| US20080311162A1 (en) * | 2007-05-16 | 2008-12-18 | Olivia Darmuzey | Solid form |
| CN101815513B (zh) * | 2007-08-07 | 2012-11-14 | 斯泰伦博斯大学 | 含有对乙酰氨基苯酚的眼用制剂 |
| KR101687580B1 (ko) | 2016-07-19 | 2016-12-20 | 주식회사 씨.월드 | 의자 등받이부와 프레임부 조립구조 |
| US11400052B2 (en) | 2018-11-19 | 2022-08-02 | Jazz Pharmaceuticals Ireland Limited | Alcohol-resistant drug formulations |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1182049A (en) * | 1981-07-13 | 1985-02-05 | Francis J. Sterbenz | Apap antacid composition |
| US4942039A (en) * | 1989-05-09 | 1990-07-17 | Miles Inc. | Effervescent analgesic antacid composition having reduced sodium content |
| DE68911501T2 (de) * | 1989-01-12 | 1994-03-31 | Bayer Ag | Analgetische antacide Brausezusammensetzung mit reduziertem Natriumgehalt. |
| US5348745A (en) * | 1989-05-09 | 1994-09-20 | Miles Inc. | Aqueous granulation solution and a method of tablet granulation |
| CA2021548A1 (en) * | 1989-09-01 | 1991-03-02 | Ronald Nash Duvall | Effervescent cold or sinus allergy medicine composition having reduced sodium content |
| DE19502789A1 (de) * | 1995-01-28 | 1996-08-01 | Dirk Krischenowski | Arzneimittel |
-
1997
- 1997-03-05 GB GBGB9704524.9A patent/GB9704524D0/en active Pending
-
1998
- 1998-02-27 US US09/380,453 patent/US6316025B1/en not_active Expired - Lifetime
- 1998-02-27 PL PL335502A patent/PL190988B1/pl unknown
- 1998-02-27 AU AU68282/98A patent/AU721851B2/en not_active Expired
- 1998-02-27 EA EA199900709A patent/EA001918B1/ru not_active IP Right Cessation
- 1998-02-27 CA CA002283408A patent/CA2283408C/en not_active Expired - Lifetime
- 1998-02-27 NZ NZ337418A patent/NZ337418A/xx not_active IP Right Cessation
- 1998-02-27 TR TR1999/02175T patent/TR199902175T2/xx unknown
- 1998-02-27 JP JP53816998A patent/JP2001513801A/ja active Pending
- 1998-02-27 CZ CZ19993148A patent/CZ294078B6/cs not_active IP Right Cessation
- 1998-02-27 ID IDW990954A patent/ID22233A/id unknown
- 1998-02-27 BR BR9807992-1A patent/BR9807992A/pt not_active Application Discontinuation
- 1998-02-27 PT PT98913664T patent/PT981334E/pt unknown
- 1998-02-27 EP EP98913664A patent/EP0981334B1/en not_active Expired - Lifetime
- 1998-02-27 ES ES98913664T patent/ES2199435T3/es not_active Expired - Lifetime
- 1998-02-27 IL IL13155298A patent/IL131552A/en not_active IP Right Cessation
- 1998-02-27 DE DE69814850T patent/DE69814850T2/de not_active Expired - Lifetime
- 1998-02-27 AP APAP/P/1999/001638A patent/AP1084A/en active
- 1998-02-27 WO PCT/EP1998/001284 patent/WO1998038983A2/en active IP Right Grant
- 1998-02-27 KR KR10-1999-7007976A patent/KR100465895B1/ko not_active Expired - Fee Related
- 1998-02-27 UA UA99094955A patent/UA59388C2/uk unknown
- 1998-02-27 SK SK1197-99A patent/SK282277B6/sk not_active IP Right Cessation
- 1998-02-27 HU HU0001501A patent/HU224983B1/hu unknown
- 1998-02-27 DK DK98913664T patent/DK0981334T3/da active
- 1998-02-27 CN CNB988045508A patent/CN100389751C/zh not_active Expired - Lifetime
- 1998-02-27 AT AT98913664T patent/ATE240720T1/de active
- 1998-03-03 AR ARP980100938A patent/AR011919A1/es active IP Right Grant
- 1998-03-03 PE PE1998000148A patent/PE68899A1/es not_active IP Right Cessation
- 1998-03-03 CO CO98011455A patent/CO4940406A1/es unknown
- 1998-03-03 MY MYPI98000911A patent/MY119722A/en unknown
- 1998-03-04 ZA ZA981832A patent/ZA981832B/xx unknown
- 1998-03-05 TW TW087103218A patent/TW508242B/zh not_active IP Right Cessation
-
1999
- 1999-09-03 BG BG103714A patent/BG64348B1/bg unknown
- 1999-09-03 NO NO19994294A patent/NO327456B1/no not_active IP Right Cessation
-
2003
- 2003-07-15 CY CY0300050A patent/CY2367B1/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SK282277B6 (sk) | Tableta alebo kapsula na prehĺtanie a spôsob jej výroby | |
| EP1058538B2 (en) | Fast disintegrating tablets | |
| US5955107A (en) | Pharmaceutical suspension tablet compositions | |
| CA2301185C (en) | Pharmaceutical preparation comprising clodronate as active ingredient and silicified microcrystalline cellulose as excipient | |
| EP0749308B1 (en) | Film coated tablet of paracetamol and domperidone | |
| CZ20002391A3 (cs) | Bleskově tající prostředek pro orální podání a způsob jeho výroby | |
| US20040170681A1 (en) | Swallow tablet comprising paracetamol | |
| SK281193B6 (sk) | Tableta so zlepšenou biodostupnosťou účinnej látky, kyseliny klodrónovej, spôsob jej výroby a použitie mikrokryštalickej celulózy | |
| PL177607B1 (pl) | Tabletka o opóźnionym uwalnianiu zawierająca sól sodową diklofenaku | |
| FI89455C (fi) | Foerfarande foer framstaellning av en farmaceutisk komposition | |
| HK1027026B (en) | Swallow tablet comprising paracetamol | |
| CA2653485A1 (en) | Prednisolone salt formulations | |
| HK1062896B (en) | Swallow tablet comprising paracetamol |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC4A | Assignment and transfer of rights |
Owner name: GLAXOSMITHKLINE DUNGARVAN LIMITED, DUNGARVAN, , IE Free format text: FORMER OWNER: SMITHKLINE BEECHAM LIMITED, BRENTFORD, MIDDLESEX, GB Effective date: 20130920 Owner name: GLAXOSMITHKLINE CONSUMER HEALTHCARE INVESTMENT, IE Free format text: FORMER OWNER: GLAXOSMITHKLINE DUNGARVAN LIMITED, DUNGARVAN, COUNTY WATERFORD, IE Effective date: 20141110 |
|
| TC4A | Change of owner's name |
Owner name: GLAXOSMITHKLINE CONSUMER HEALTHCARE INVESTMENT, IE Effective date: 20141110 |
|
| MK4A | Expiry of patent |
Expiry date: 20180227 |